 |
 |
| |
Sign
up today for free email alerts of new market research reports in
your industry. |
|
 |
|
 |
|
| 
Strategic Perspectives: Commercial Opportunites
in Depression - Generating Revenue Growth In Symptoms And
Comorbidities
|
|
Countries covered: Japan, France, Germany, Italy,
Spain, United Kingdom, United States
Introduction:The growth
of the antidepressant market over the last decade has been
built upon increasingly sophisticated marketing strategies.
This has not only made the depression market highly
competitive, but also produced an expanded patient potential
as manufacturers move their products into non-traditional
markets. Scope: * Analysis of depressive symptoms in
presenting patients from the seven major markets * Analysis of
depressive symptoms throughout the course of the illness in
treated patients from the seven major markets * The level of
comorbidity of anxiety and non-anxiety disorders in treated
depression patients from the seven major markets * Analysis of
the leading products in each of these areas of the depression
market * Datamonitor’s strategic recommendations for marketed
and pipeline drugs. Report Highlights: Traditionally,
manufacturers have sought indications in anxiety disorders to
ensure product growth. However, following the licensing of
fluoxetine for bulimia and bupropion for smoking cessation,
Datamonitor has identified a third phase of potential
development for antidepressant drugs. By targeting non-anxiety
disorders, manufacturers are continually escalating the
patient potential for their drugs, which is crucial if the
rapid expansion of the antidepressant is to be continued in
this decade.The understanding of the prevalence level of
depressive symptoms, both at presentation and throughout the
illness, is key for all antidepressant manufacturers to devise
successful marketing strategies. Furthermore, the competitive
landscape in these sub-markets is crucial to understand, if a
significant return on investment is to be achieved.Reasons to
Purchase: * Understand the prevalence level of depressive
symptoms in the treated population * Enhance your
understanding of how these symptoms respond to current
therapies * Identify the prevalence level of specific anxiety
disorders in the treated depression population * Increase your
understanding of the prevalence level of non-anxiety disorders
in depression patients * Discover the commercial and strategic
opportunities that exist in these areas of the depression
market
| |
|
0
items 
